Boehringer Ingelheim - Press Release

Boehringer Ingelheim significantly expands its supply centre for China

Wed, 14 Dec 2011 00:00:00 GMT

Bracknell, United Kingdom, 14 December 2011</strong> – Boehringer Ingelheim announced today that the company intends to invest 70 million Euro to expand its manufacturing plant in the Zhangjiang High-Tech Park in Shanghai into a strategically important supply center for China. The goal of this project is to bring more health to more patients and to continuously improve Boehringer Ingelheim’s product competitiveness and enlarge its market share.</p>

With the expansion until end of 2013, the number of employees will rise significantly from 240 today to 400, the production capacity will be doubled.</p>

“We want to expand our Zhangjiang plant, primarily to meet the demand for more health in China. It also shows our continuous commitment to China and specifically Shanghai”, said Professor Dr Wolfram Carius, responsible for the Corporate Board Division Operations and Human Resources. “Our vision is to transform our Shanghai plant into a launch site in Boehringer Ingelheim’s global Operations network.”</p>

The project intends to build a modular and lean manufacturing facility on the current production site. It will be able to produce marketed products and new pipeline products. The objective to have world-class production through a lean manufacturing approach will be supported by the optimisation of material flow and by our highly qualified employees.</p>

In the first phase, which will be completed by the end of December 2013, a packaging center for ampoules and solids and a new automatic warehouse will be constructed. Furthermore, a new laboratory building for development activities will be set up on the site. In the second phase, to be concluded until the end of 2014, the existing solids manufacturing facility will be revamped and upgraded with new technologies.</p>

The pharmaceutical industry is currently in the focus of Shanghai’s economic strategy.  Boehringer Ingelheim China’s strategy is in tune with the economic structure transformation advocated by the government and will lead the company into a new phase of development.  “We are committed to meeting the growing demand of China's pharmaceutical market and to bringing more health to patients and their families”, said David Preston, Chief Executive Officer of Boehringer Ingelheim China.</p>

Since it entered the Chinese market in 1994, Boehringer Ingelheim has expanded its product range to cover respiratory, cardiovascular, central nervous system and other important therapeutic areas. In the forthcoming years, the company will continue to expand, including the therapeutic areas diabetes, oncology and stroke prevention.</p>

~Ends~</span></p>

 </p>

Boehringer Ingelheim </strong></span>
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.</span>
A central element of Boehringer Ingelheim’s culture is to be socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim’s endeavors.</span></p>

In 2010, Boehringer Ingelheim posted net sales of about 12.6 billion euro while spending almost 24% of net sales in its largest business segment Prescription Medicines on research and development.</span></p>

For more information please visit www.boehringer-ingelheim.co.uk</a></span></p>

For further information, please contact:</strong></span>
Duncan Cantor</span>
Communications Director</span>
Boehringer Ingelheim Limited</span>
Tel: +44 (0)1344 741235</span>
duncan.cantor@boehringer-ingelheim.com</a></span></p>

Winners of the Making More Health competition bring fresh innovation to solving problems in health

Fri, 9 Dec 2011 00:00:00 GMT

Bracknell, United Kingdom, 7 December</strong> - Three winners whose solutions are tackling today’s most pressing health problems have emerged from Making More Health: Achieving Individual, Family and Community Well-being, a competition hosted by Ashoka Changemakers and Boehringer Ingelheim, one of the world’s 20 leading pharmaceutical companies.</p>
The winners’ innovations describe new health care delivery models for extremely impoverished communities, the novel use of local human resources to expand the capacity of medical clinics, and holistic approaches to sustainable health. The public voted to select the three winners from a field of finalists chosen by a panel of expert judges. The judges included Aman Bhandari of the U.S. Department of Health and Human Services, Carol A. Dahl, executive director of The Lemelson Foundation, and Prof. Andreas Barner, chairman of the board of managing directors for Boehringer Ingelheim. More than 470 entries were received from 82 countries.</p>
“Creating more health for individuals, families and communities requires new strategies and fresh ways of thinking," said Prof. Andreas Barner, chairman of the Board of Managing Directors for Boehringer Ingelheim. "I’m impressed by the quality of the innovations participating in this competition. Being able to identify initiatives of this caliber is an important asset for the health field."</p>
The online competition is part of a three-year global initiative led by Ashoka Changemakers and Boehringer Ingelheim to identify and support innovations from around the world that transform the field of health to sustainably increase individual, family, and community well-being.</p>
“The Making More Health competition is a first step toward achieving greater impact in health and health care globally,” added Diana Wells, president of Ashoka. “We are delighted that Boehringer Ingelheim has chosen to engage in a three-year partnership to continue its support of social entrepreneurs with the unique creativity and drive to take on such an imperative global issue.”</p>
Each winner will receive a prize of US $10,000. The winners are:</p>
• ColaLife: Piggybacking Simple Medicines on Cola Supply Chains, to  Save Lives in Underserved Rural Areas in Africa, Zambia
• Saúde Criança: Holistic Health Solutions for Families in Favelas,Brazil
• Unite For Sight, Ghana</p>
 </p>
~Ends~</strong></p>

For further information, please contact:</strong>
Duncan Cantor
Communications Director
Boehringer Ingelheim Limited
Tel: +44 (0)1344 741235
duncan.cantor@boehringer-ingelheim.com</a></p>
Boehringer Ingelheim </strong>
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
A central element of Boehringer Ingelheim’s culture is to be socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim’s endeavors.</p>
In 2010, Boehringer Ingelheim posted net sales of about 12.6 billion euro while spending almost 24% of net sales in its largest business segment Prescription Medicines on research and development.</p>
For more information please visit www.boehringer-ingelheim.co.uk</a></p>
About Ashoka Changemakers®</strong>
Ashoka Changemakers is a community of action that connects social entrepreneurs around the globe to share ideas, inspire, and mentor each other. Through its online collaborative competitions and open-source process, Changemakers.com is one of the world’s most robust spaces for launching, discussing, and funding ideas to solve the world’s most pressing social problems. Changemakers builds on Ashoka's three-decade history and belief that we all have the ability to be a Changemaker.</p>
http://www.Changemakers.com</a></p>

 </p>

Boehringer Ingelheim expands its Business with Biosimilars

Mon, 26 Sep 2011 00:00:00 GMT

Bracknell, England,  September 26, 2011</strong> - As part of its corporate strategy Boehringer Ingelheim announced today to establish a new separate business for the development and commercialization of own biosimilars.</p>
Boehringer Ingelheim started more than 30 years ago as a pioneer in biopharmaceuticals with the development and manufacturing of biopharmaceutical therapeutics. Today Boehringer Ingelheim Biopharmaceuticals is one of the leading companies in this field straight following its strategy to serve best in class development and manufacturing for its clients and Boehringer Ingelheim itself.</p>
“We believe that biosimilars will become a major part of the biopharmaceutical market and will enable many more patients access to important medicines”, commented Prof. Dr. Wolfram Carius, member of the Board of Managing Directors and responsible for Operations. “We feel confident that we are able to leverage our capabilities in product development, supply and clinical expertise at Boehringer Ingelheim to offer high quality Biosimilars understanding patients’ needs.”</p>
~Ends~</strong></p>
For further information please contact:
</strong>Duncan Cantor
Director of Communications
Duncan.Cantor@boehringer-ingelheim.com</a>
Tel: +44 (0)1344 74 1155
Twitter: www.twitter.com/boehringer</a></p>

About Boehringer Ingelheim
</strong>The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.</p>
As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim’s endeavors.</p>
In 2010, Boehringer Ingelheim posted net sales of about 12.6 billion euro while spending almost 24% of net sales in its largest business segment Prescription Medicines on research and development.</p>
For more information please visit
http://www.boehringer-ingelheim.com</a>
 </p>

Boehringer Ingelheim wins Frost & Sullivan Award 2011 for outstanding service in the Biopharmaceutical Contract Manufacturing

Wed, 7 Sep 2011 00:00:00 GMT

Bracknell, England, September 7, 2011 </strong>– Boehringer Ingelheim has received the '2011 European Bio Pharmaceutical Contract Manufacturing Competitive Strategy Leadership Award' from Frost & Sullivan.</p>
The analysts of Frost & Sullivan recognized Boehringer Ingelheim Biopharmaceuticals as a global contract manufacturer who delivers excellence and best practices to its customers and collaboration partners. The Boehringer Ingelheim performance was measured against key competitors in the same market focusing on the criteria: leverage of competitive intelligence, execution of competitive strategy, impact on market share, competitive brand positioning and impact on customer satisfaction and value.</p>
"This award is an important recognition for our contract manufacturing organization and a great confirmation for continued drive to put our customers first”, stated Simon Sturge, Corporate Senior Vice President Biopharmaceuticals at Boehringer Ingelheim.  “We will not rest on our laurels and will continue to further improve our customer services to also deliver reliable and best quality in the future. With our newly acquired biopharma development- and manufacturing facility in Fremont, California, Boehringer Ingelheim has already taken the next important step to further strengthen our global customer orientation and flexibility”.</p>
Contact:
</strong>Duncan Cantor
Director of Communications44 (0)1344 74 1155
Duncan.Cantor@boehringer-ingeheim.com</a>
Twitter: @BoehringerUK</p>
 More information:
</strong>www.biopharma-cmo.com</a>
 
About Boehringer Ingelheim
</strong>The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
A central element of Boehringer Ingelheim’s culture is to be socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim’s endeavors.</p>
In 2010, Boehringer Ingelheim posted net sales of about 12.6 billion euro while spending almost 24% of net sales in its largest business segment Prescription Medicines on research and development.</p>
For more information please visit www.boehringer-ingelheim.co.uk</a></p>

 </p>

BI's innovative medicines deliver positive first half year results in Europe

Tue, 9 Aug 2011 00:00:00 GMT

Bracknell, England, 9 August 2011 – Boehringer Ingelheim has in the first half of 2011 once again grown in local currency terms compared to the previous year (+ 4 percent). Consolidation in euros shows growth of 2.6 percent, with total net sales of EUR 6.4 billion against EUR 6.2 billion in the first half of the previous year.
 
“We are pleased that Boehringer Ingelheim has further developed positively through innovative medications”, Professor Andreas Barner, Chairman of the Board of Managing Directors, underlined. “Our vision – Value through Innovation – thereby proves itself sustainably as the basis of our company.”</p>
Overall, Prescription Medicines’ net sales amounted to EUR 4.9 billion in the first half-year, broadly in line with the previous year’s level.  After currency adjustment and taking into account structural business conditions (e. g. the expiry of exclusivity on medications in the USA and Germany), business grew by 10 percent in local currency terms, particularly in the USA, Japan and Canada.  Established prescription medicines, such as Spiriva® and Micardis®, showed market increases, with growth of 10 and 11 percent respectively. </p>
“For Boehringer Ingelheim the first half of business year 2011 is characterised in turnover terms by successful new launches. A good earnings position overall has enabled us to activate again higher investment in research and development” explained Hubertus von Baumbach, Member of the Board of Managing Directors responsible for Finance. Operating income in the first half-year has developed more positively compared to the previous year.</p>
The turnover of the Consumer Health Care business amounted to EUR 667 million, or 11 percent growth towards the first six months of the previous year in local currency terms. The gratifying increase in net sales of cold medications in Europe contrasted with depressed growth in the self-medication business in Japan (- 6 percent in local currency terms). The prolonged stagnation of the self-medication market was furthermore negatively impacted by the consequences of the earthquake and the tsunami.</p>
In the emerging markets, Boehringer Ingelheim was able to increase its Human Pharmaceuticals’ net sales by some 12 percent overall to EUR 890 million. Here, China, Russia, Venezuela and Mexico were the companies with the strongest growth.</p>
The Industrial Customer business achieved EUR 332 million net sales in the first half of 2011, or 13 percent more than during the same period of the previous year.  This development is primarily attributable to increased turnover in the development and production of biopharmaceuticals for third party customers. Other third party business was reduced by 9 percent.</p>
The Animal Health business achieved net sales of EUR 468 million in the first half of 2011, thereby growing three percent over the first half of last year in local currency terms. The important growth driver was again the innovative swine vaccine Ingelvac® CircoFLEX, with net sales growth of 10 percent compared to the same period of the previous year.</p>
New substances from the company’s own research and development made further progress, Prof. Barner stressed. A row of new biological and chemical active ingredients were transferred from the preclinical stage to clinical development. Furthermore, substances in the late development phases were progressed according to plan.</p>
The personnel capacity of Boehringer Ingelheim’s international group of companies, as of 30 June 2011, stood at 42,486, or 4.8 percent (+1,957 positions) higher compared to the first half of the previous year.</p>
~Ends~</p>

For further information, please contact the press office on +44 (0)1344 74 1155

Boehringer Ingelheim</strong>
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
A central element of Boehringer Ingelheim’s culture is to be socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim’s endeavors.</p>
In 2010, Boehringer Ingelheim posted net sales of about 12.6 billion euro while spending almost 24% of net sales in its largest business segment Prescription Medicines on research and development.</p>
For more information please visit www.boehringer-ingelheim.co.uk</a></p>

 </p>

Ashoka and Boehringer Ingelheim announce a global partnership for Making More Health

Tue, 21 Jun 2011 00:00:00 GMT

Paris, France, 21 June, 2011 - Ashoka and Boehringer Ingelheim announced today that they will launch a three-year global initiative to improve health in communities around the world.  The “Making More Health” initiative will promote healthy individuals, families and communities by identifying and supporting the most promising solutions to challenge health problems.

The partnership includes support for a series of programs aimed at identifying innovative health solutions, including the election of 50 leading social entrepreneurs (elected as “Ashoka Fellows”) whose ideas are driving cutting-edge systemic solutions in the field of health. In addition, two web-based changemakers competitions will open an invitation to the public to submit new ideas on how to improve health in underserved communities. “Making More Health” will also focus on the next generation of changemakers through a youth venture program to engage young people in designing health solutions for their communities.

Boehringer Ingelheim will support “Making More Health” by engaging its 42,000 employees worldwide in various capacities to help spread an understanding and appreciation of social entrepreneurship and health innovation within their own communities.

“Making More Health brings together two organizations committed to finding innovative people and ideas to help shape the future of the health sector,” said Professor Dr Andreas Barner, chairman of the board of managing directors at Boehringer Ingelheim.  “Through this partnership we will bring forth meaningful and sustainable solutions that can achieve individual and family well-being in communities around the globe.”   

Ashoka’s Chair, Bill Drayton, commented: “Some parts of how the world deals with health are highly creative, most especially the development of new pharmaceuticals, an area where Boehringer Ingelheim has made contribution after contribution for 125 years. Much of the rest of the system, however, has fallen way behind the need. The Making More Health partnership creates a global and business/social alliance led by top entrepreneurs and open to all that we believe will bring big changes to the entire system.” 

To date, “Making More Health” has supported four leading Ashoka social entrepreneurs in the health sector, including Rebecca Onie, founder of Health Leads in the United States; Michael Hoffmann founder of Discovering Hands in Germany; Guillaume Bapst, founder of ANDES in France; and Luh Ketut Suryani, founder of the Suryani Institute for Mental Health in Indonesia. </p>
About Boehringer Ingelheim
</strong>The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim’s endeavors.</p>
www.boehringer-ingelheim.co.uk</a></p>
About Ashoka
</strong>Ashoka is the global association of the world’s leading social entrepreneurs—men and women with system changing solutions for the world’s most urgent social problems.  Since 1981, Ashoka has helped launch over nearly 3000 leading social entrepreneurs as Ashoka Fellows, providing them with living stipends, professional support, and access to a global network of peers in 70 countries. Ashoka is known around the world for launching the field of social entrepreneurship and its current work in creating an “Everyone a Changemaker” world encouraging innovation and problem-solving from all.</p>
www.Ashoka.org</a>
 </p>

Boehringer Ingelheim triumphs in Sunday Times survey

Thu, 3 Mar 2011 00:00:00 GMT

Boehringer Ingelheim triumphs in Sunday Times survey</strong></p>
Bracknell-based pharmaceutical company, Boehringer Ingelheim, has done it again!  It’s been voted as one of the best companies to work for in the Sunday Times ‘Top 100 ‘Best Companies’ survey – the eighth time the company has been listed in these annual awards. </p>
The Sunday Times’ Best Companies to Work For survey is based on employee response and through extensive questioning, identifies best practice and then ranks companies according to employee satisfaction.</p>
This year, more companies than ever before (nearly 1,200) competed for placement in this coveted survey and Boehringer Ingelheim came in within the top 10%.</p>
Drew Owenson, Managing Director of Boehringer Ingelheim UK, is delighted with the result.</p>
“To be ranked in the Top 100 Companies is a fantastic reflection of our unique culture, one that embraces pride, trust and valuing people.” </p>
In celebration of this achievement the company will be making a donation of £12,500 to its charity of the year, Barnardo’s.  This will help pay for over-night breaks for children or young people with disabilities.  These stays give the parents and families an important break from the demands of caring for a disabled child.</p>
 </p>
ENDS
For further information, please contact Communications on 01344 742779.</p>
Notes for Editors:
The Sunday Times’ 100 Best Companies to Work For competition is a guide to the best employers in Britain.  It is the biggest and most comprehensive survey of the British workplace ever undertaken.
 </p>

Boehringer Ingelheim and Eli Lilly and Company Announce Strategic Alliance to Bring New Diabetes Treatments to Patients Worldwide

Tue, 11 Jan 2011 00:00:00 GMT

Major diabetes care agreement centers on four pipeline compounds representing several of the largest and most promising product classes.</i></li>
Companies will jointly develop and commercialize a pipeline of oral diabetes agents and basal insulin analogues. The alliance also includes the option</i> to co-develop and co-commercialize an anti-TGF-beta monoclonal antibody.</i></li>
Boehringer</i> Ingelheim’s innovative late-stage diabetes pipeline drives its expansion into new therapeutic area, supplemented by two basal insulin analogues, currently under development from Lilly.</i></li>
Agreement furthers Lilly’s commitment to offer one of the broadest portfolios in diabetes care and provide together with </i>Boehringer</i> Ingelheim more options for people with diabetes, their health care providers and payers.</i></li>
Boehringer</i> Ingelheim will host a media event; Lilly will host an investor conference call today to discuss the content and benefits of the alliance.</i></li> </ul> Ingelheim/Germany and Indianapolis/USA – Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced a global agreement to jointly develop and commercialize a portfolio of diabetes compounds currently in mid- and late-stage development. Included are Boehringer Ingelheim’s two oral diabetes agents—linagliptin and BI10773—as well as Lilly’s two basal insulin analogues—LY2605541 and LY2963016 as well as the option to co-develop and co-commercialize Lilly’s anti-TGF-beta monoclonal antibody.</div>
 </div>
Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor discovered by Boehringer Ingelheim and being developed as an oral once-daily tablet for the treatment of Type 2 diabetes.  It is currently under regulatory review in the U.S., Europe and Japan. Boehringer Ingelheim’s BI10773, a sodium-dependent glucose co-transporter-2 (SGLT-2) inhibitor, began enrollment in Phase III clinical trials last year. It belongs to a new, emerging class of diabetes compounds that block tubular reabsorption of glucose in the kidney.  Currently there are no SGLT-2 inhibitors approved for use.</div>
 </div>
Lilly’s two basal insulin analogue candidates are expected to enter Phase III clinical testing in 2011. Lilly’s two basal insulin analogue candidates are LY2605541, a structurally novel basal insulin analogue, and LY2963016, a new insulin glargine product. The agreement also includes an option for Boehringer Ingelheim to co-develop and co-commercialize another Lilly diabetes molecule, an anti-TGF-beta monoclonal antibody, which is currently in Phase II of clinical testing in patients with diabetes with chronic kidney disease.</div>
 </div>
The alliance will leverage the collective scientific expertise and business capabilities of two leading research-driven pharmaceutical companies to address patient needs arising from the growing global diabetes epidemic.</div>
 </div>
“We are very excited about this new and extensive alliance with Boehringer Ingelheim, with whom we have partnered successfully in the past,” said John C. Lechleiter, Ph.D., Lilly chairman and chief executive officer. “Working together, we will comprise one of the most robust diabetes pipelines in the pharmaceutical industry. For Lilly, this alliance expands our range of offerings for people with diabetes, strengthens our diabetes care capabilities and offers the prospect of near-term revenue opportunities as we address the upcoming loss of patent exclusivity for several of our products.”</div>
 </div>
“Boehringer Ingelheim and Lilly have agreed to form a strategic alliance in diabetes at a time point when we at Boehringer Ingelheim are entering another new therapeutic area with innovative compounds out of our own Research and Development. This cooperation will give Boehringer Ingelheim and Lilly the combined benefits of Lilly’s expertise in the diabetes market and two basal insulin analogues as well as Boehringer Ingelheim’s rich and innovative late-stage pipeline.” said Prof. Andreas Barner, Chairman of the Board of Managing Directors of Boehringer Ingelheim.</div>
 </div>
Under the terms of the agreement, Lilly will make an initial one-time payment to Boehringer Ingelheim of €300 million. Boehringer Ingelheim will be eligible to receive up to a total of €625 million in success-based regulatory milestones for linagliptin and BI10773. Lilly will be eligible to receive up to a total of $650 million in success-based regulatory milestones on its two basal insulin analogues. Should Boehringer Ingelheim elect to opt-in to the Phase III development and potential commercialization of the anti-TGF-beta monoclonal antibody, Lilly would be eligible for up to $525 million in opt-in and success-based regulatory milestone payments. The companies will share ongoing development costs equally. Upon successful regulatory approval of any product resulting from the alliance, the companies will equally share in the product’s commercialization costs and gross margin. Each company will also be entitled to potential performance payments</span> on sales of the molecules they contribute to the collaboration.</div>
 </div>
As a result of this transaction, Lilly expects 2011 earnings per share dilution in the range of $0.45-$0.</span>50, including a charge of approximately $0.27 per share related to the one time payment. Assuming a successful launch of linagliptin, Lilly anticipates progressively and significantly less dilution in 2012 and 2013, no dilution to slight accretion in 2014, and more significant accretion in 2015 and beyond. The 2011 financial impact of this transaction will be reflected in Lilly’s 2011 financial guidance, which will be provided as part of the fourth quarter and full-year 2010 financial results announcement on </span>January 27, 2011</span>.</span></div>
 </div>
Lilly Conference Call and Webcast</b></div>
Lilly will conduct a conference call with the investment community and media today at 10:00 a.m. EST to discuss today’s announcement. Investors, media and the general public can access a live webcast of the conference call through the Webcasts & Presentations link that will be posted on Lilly's website at www.lilly.com</a>. The webcast of the conference call will be available for replay through </span>February 11, 2011.</div>
 </b></div> Boehringer</b> Ingelheim Press Conference and Webcast</b></div> Boehringer Ingelheim will host a web-enabled press conference in Frankfurt, Steigenberger Airport Hotel with the media today at 13:30 h CET to discuss today’s announcement. Media not in attendance can access a live webcast of the press conference through this link: http://bit.ly/av-events</span>. The webcast of the press conference will be available for replay through January 18, 2011.</a></div>
 </b></div>
About Diabetes </b></div>
Diabetes affects an estimated 285 million adults worldwide and more than 24 million people in the U.S.^{(1,2) </sup>Approximately 90-95 percent of those affected have type 2 diabetes. Diabetes costs approximately $174 billion per year in direct and indirect medical expenses in the U.S.^{(3)</sup></div>}}
According to the Centers for Disease Control and Prevention's National Health and Nutrition Examination Survey, approximately 60 percent of people with diabetes do not achieve their target blood sugar levels with their current treatment regimen.^{(4)</sup></div>}
 </div>
About </b>Boehringer</b> Ingelheim</b></div> The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally, with 142 affiliates in 50 countries and more than 41,500 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine. For more information on Boehringer Ingelheim, please see www.boehringer-ingelheim.co.uk</span></a></div>
 </b></div>
About Lilly Diabetes</b></div> For more than 85 years, Lilly has been a worldwide leader in pioneering industry-leading solutions to support people living with and treating diabetes. Lilly introduced the world's first commercial insulin in 1923, and remains at the forefront of medical and delivery device innovation to manage diabetes. Lilly is also committed to providing solutions beyond therapy - practical tools, education, and support programs to help overcome barriers to success along the diabetes journey. At Lilly, the journeys of each person living with or treating diabetes inspire ours. For more information, visit www.lillydiabetes.com.</div>
 </b></div> About Eli Lilly and Company</b></div> Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com</a>.</div>
 </div>
 </div>
This press release contains forward-looking statements that are based on Lilly’s and Boehringer Ingelheim’s current expectations, but actual results may differ materially due to various factors. There are significant risks and uncertainties in pharmaceutical research and development. There can be no guarantees with respect to pipeline products (including all of the compounds discussed in this press release) that the products will receive the necessary clinical and manufacturing regulatory approvals or that they will prove to be commercially successful. In addition, there can be no guarantee that the companies will realize the financial and commercial results anticipated from this collaboration. Other risk factors that may affect Lilly’s results can be found in the company's latest Forms 10-K and 10-Q filed with the U.S. Securities and Exchange Commission. The companies undertake no duty to update forward-looking statements.</span></font></div>
 </div>
#              #              #</span></font></div>
 </div>
References:</font></b></div>
(1) The International Diabetes Federation Diabetes Atlas. Available at: http://www.diabetesatlas.org/content/some-285-million-people-worldwide-will-live-diabetes-2010. Accessed September 10, 2010. </font></div>
(2) Diabetes Statistics. American Diabetes Association. Available at: http://www.diabetes.org/diabetes-basics/diabetes-statistics/. Accessed September 10, 2010. </font></div>
(3) Direct and Indirect Costs of Diabetes in the United States. American Diabetes Association. Available at: http://www.diabetes.org/how-to-help/action/resources/cost-of-diabetes.html. Accessed September 10, 2010. </font></div>
(4) Saydah SH, Fradkin J and Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA</i>. 2004;291:335-42. </font></div>
 </div>